Optimal pathways are being implemented for colorectal, lung, and head- and-neck cancers, with prostate and hepato-pancreato-biliary pathways in development. Latest figures showed 94.8% of patients began treatment within 31 days of a decision to treat, with a median wait of two days, jointly the lowest on record.